Biomarker, BioAnalysis and BioInformatics
Preclinical biomarker discovery strategies help to identify potential therapeutic targets, assess the safety and effectiveness of new compounds, and inform the design of clinical trials. If introduced early in preclinical studies, they can play a key role in reducing the cost and time required for drug development.
Cystopathic Diseases
Discover a unique high content screening platform for Autosomal Dominant Polycystic Kidney Disease and 3D cyst swelling assay for Cystic Fibrosis. Our unique high content screening platforms enables the recapitulation of the in vivo disease phenotype with robust functional readouts.
Immune-Mediated Inflammatory Diseases (IMID)
Our catalogue of inflammation models recapitulates key clinical and pathological features of human disease, forming an integrated platform for preclinical drug development.
Immuno-Oncology
Immuno-oncology (I/O) being such a highly diverse therapeutic area requiring specialist knowledge to progress in the field. The development of new immunotherapies still faces many challenges. Crown Bioscience have gained unrivalled preclinical and translational I/O experience through our partnerships with the world's leading I/O companies.
Oncology
Accelerate your oncology program using our comprehensive suite of in vivo, in vitro and ex vivo biological services